264 related articles for article (PubMed ID: 23416052)
1. Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.
Ogembo JG; Kannan L; Ghiran I; Nicholson-Weller A; Finberg RW; Tsokos GC; Fingeroth JD
Cell Rep; 2013 Feb; 3(2):371-85. PubMed ID: 23416052
[TBL] [Abstract][Full Text] [Related]
2. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells.
Kozono Y; Abe R; Kozono H; Kelly RG; Azuma T; Holers VM
J Immunol; 1998 Feb; 160(4):1565-72. PubMed ID: 9469411
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
[TBL] [Abstract][Full Text] [Related]
4. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
Smith NA; Coleman CB; Gewurz BE; Rochford R
J Virol; 2020 May; 94(11):. PubMed ID: 32238579
[TBL] [Abstract][Full Text] [Related]
5. Regulation of humoral immune responses by CD21/CD35.
Chen Z; Koralov SB; Kelsoe G
Immunol Rev; 2000 Aug; 176():194-204. PubMed ID: 11043778
[TBL] [Abstract][Full Text] [Related]
6. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation.
Gommerman JL; Oh DY; Zhou X; Tedder TF; Maurer M; Galli SJ; Carroll MC
J Immunol; 2000 Dec; 165(12):6915-21. PubMed ID: 11120817
[TBL] [Abstract][Full Text] [Related]
7. Role of complement receptors CD21/CD35 in B lymphocyte activation and survival.
Carroll M
Curr Top Microbiol Immunol; 1999; 246():63-8; discussion 69. PubMed ID: 10396040
[TBL] [Abstract][Full Text] [Related]
8. Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection.
Arredouani MS; Bhasin MK; Sage DR; Dunn LK; Gill MB; Agnani D; Libermann TA; Fingeroth JD
J Virol; 2014 May; 88(10):5559-77. PubMed ID: 24600013
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection.
Shannon-Lowe C; Rowe M
PLoS Pathog; 2011 May; 7(5):e1001338. PubMed ID: 21573183
[TBL] [Abstract][Full Text] [Related]
10. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
Young KA; Chen XS; Holers VM; Hannan JP
J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
[TBL] [Abstract][Full Text] [Related]
11. CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus.
Fingeroth JD; Diamond ME; Sage DR; Hayman J; Yates JL
J Virol; 1999 Mar; 73(3):2115-25. PubMed ID: 9971794
[TBL] [Abstract][Full Text] [Related]
12. CD21/CD35 in B cell activation.
Carroll MC
Semin Immunol; 1998 Aug; 10(4):279-86. PubMed ID: 9695184
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21.
Yoshiyama H; Imai S; Shimizu N; Takada K
J Virol; 1997 Jul; 71(7):5688-91. PubMed ID: 9188650
[TBL] [Abstract][Full Text] [Related]
14. Characterization of an Epstein-Barr virus receptor on human epithelial cells.
Birkenbach M; Tong X; Bradbury LE; Tedder TF; Kieff E
J Exp Med; 1992 Nov; 176(5):1405-14. PubMed ID: 1383386
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.
Young KA; Herbert AP; Barlow PN; Holers VM; Hannan JP
J Virol; 2008 Nov; 82(22):11217-27. PubMed ID: 18786993
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
17. Expression of complement receptors 1 (CR1/CD35) and 2 (CR2/CD21), and co-signaling molecule CD19 in cattle.
Pringle ES; Firth MA; Chattha KS; Hodgins DC; Shewen PE
Dev Comp Immunol; 2012 Dec; 38(4):487-94. PubMed ID: 22989997
[TBL] [Abstract][Full Text] [Related]
18. Complement receptor type 1 (C3b/C4b receptor; CD35) and complement receptor type 2 (C3d/Epstein-Barr virus receptor; CD21).
Fearon DT; Ahearn JM
Curr Top Microbiol Immunol; 1990; 153():83-98. PubMed ID: 2153507
[No Abstract] [Full Text] [Related]
19. A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.
Ogembo JG; Muraswki MR; McGinnes LW; Parcharidou A; Sutiwisesak R; Tison T; Avendano J; Agnani D; Finberg RW; Morrison TG; Fingeroth JD
J Transl Med; 2015 Feb; 13():50. PubMed ID: 25885535
[TBL] [Abstract][Full Text] [Related]
20. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV.
Luxembourg AT; Cooper NR
J Immunol; 1994 Nov; 153(10):4448-57. PubMed ID: 7525704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
